Advertisement
Advertisement
BBIO
BridgeBio Pharma, Inc. Common Stock
66.13
USDSponsored
-3.53
-5.07%
May 15, 15:59 UTC -4
Closed
Pre-Market
66.08
-0.05
-0.07%
BBIO Earnings Reports
Positive Surprise Ratio
BBIO beat 8 of 28 last estimates.
29%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$228.74M
/-$0.58
Implied change from Q1 26 (Revenue/ EPS)
+17.59%
/-30.95%
Implied change from Q2 25 (Revenue/ EPS)
+106.88%
/-38.95%
BridgeBio Pharma, Inc. Common Stock earnings per share and revenue
On May 07, 2026, BBIO reported earnings of -0.84 USD per share (EPS) for Q1 26, missing the estimate of -0.69 USD, resulting in a -21.37% surprise. Revenue reached 194.51 million, compared to an expected 181.50 million, with a 7.17% difference. The market reacted with a -0.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.58 USD, with revenue projected to reach 228.74 million USD, implying an decrease of -30.95% EPS, and increase of 17.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dr. Reddy's Laboratories Limited - ADR
Report Date
May 12, 2026 For Q4 26
Estimate
$11.40
Actual
$2.65
Surprise
-76.76%
Supernus Pharmaceuticals, Inc.
Report Date
May 05, 2026 For Q1 26
Estimate
$0.30
Actual
$0.60
Surprise
+97.69%
Taysha Gene Therapies, Inc. Common Stock
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.12
Surprise
-20.48%
Amphastar Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.71
Actual
$0.42
Surprise
-41.59%
Personalis, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-5.42%
Assembly Biosciences, Inc
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.58
Actual
-$0.54
Surprise
+7.12%
Metagenomi Therapeutics, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-14.68%
FAQ
What were BridgeBio Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, BridgeBio Pharma, Inc. Common Stock reported EPS of -$0.84, missing estimates by -21.37%, and revenue of $194.51M, 7.17% above expectations.
How did the market react to BridgeBio Pharma, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.09%, changed from $67.45 before the earnings release to $67.39 the day after.
When is BridgeBio Pharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for BridgeBio Pharma, Inc. Common Stock's next earnings report?
Based on 13
analysts, BridgeBio Pharma, Inc. Common Stock is expected to report EPS of -$0.58 and revenue of $228.74M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement